Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Dementia & Alzheimer’s — Weekly Report — October 19, 2026

Home/Health Insights/Dementia & Alzheimer's — October 19 – October 26, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Dementia & Alzheimer's
Updated Monday · November 16, 2026
Dementia & Alzheimer's · October 19 – October 26, 2026

Dementia & Alzheimer's
Weekly Report

This week's data 12 new clinical trials registered across 7 countries, with 958 trials actively recruiting patients worldwide.
Week of October 19 – October 26, 2026
  • 12 new clinical trials registered across 7 countries.
  • 958 trials actively recruiting patients worldwide.
  • Notable trial: MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) (5000 patients).
  • 1,298 new research papers published.
  • Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 19 – October 26, 2026
New Trials This Week
12.
registered Oct 19–Oct 26
Recruiting Now
958
active trials seeking patients
Countries
7
with active trials this week
Papers Published
1,298
new studies this week
Phase 3 Trials
0
late-stage trials this week
Fig. 01

Trials by country

Count · October 19 – October 26, 2026
China
7
United States
3
Italy
2
South Korea
1
Not specified
1
Jordan
1
Canada
1
0 2 4 6 7
total
Fig. 02

Trials by phase

Distribution · October 19 – October 26, 2026

New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

12 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Fuzhou Aging Brain Health Initiative Dementia & Alzheimer's · Fujian Medical University Union Hospital (NCT07891429) Other Recruiting 3,000 China
02 SmartEnLite for Nursing Home Residents With Dementia Dementia & Alzheimer's · Penn State University (NCT07883291) Other Not Yet Recruiting 300 United States
03 TPSAlz - Transcranial Pulse Stimulation in Alzheimer's Disease Dementia & Alzheimer's · IRCCS San Raffaele Roma (NCT07883148) Other Completed 52 Italy
04 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants Dementia & Alzheimer's · Beijing Suncadia Pharmaceuticals Co., Ltd (NCT07889349) Phase 1 Not Yet Recruiting 50 China
05 Inpatient Hospice Transitions Checklist Dementia & Alzheimer's · New York University (NCT07889830) Other Not Yet Recruiting 150 United States
06 The Effects of an Empower_ICE-Fit Program in PLwD Living at Home Dementia & Alzheimer's · The University of Hong Kong (NCT07889635) Other Not Yet Recruiting 304 China
07 Clinical Cohort of Memory Disorders Dementia & Alzheimer's · Yonsei University (NCT07880275) Other Recruiting 1,550 South Korea
08 EXercise-induced PhysioLogical Adaptations In Neurological Disorders Dementia & Alzheimer's · Brigham and Women's Hospital (NCT07883720) Other Recruiting 240 United States
09 Human-LLM Conversations as a Digital Signature of Cognitive Performance in Adults Dementia & Alzheimer's · Technion, Israel Institute of Technology (NCT07890207) Other Not Yet Recruiting 100 N/A
10 Shedding Light on Dementia With Lewy Bodies: a Multimodal 'Bright Light Treatment' to Modulate Brain Functions Dementia & Alzheimer's · Azienda Usl di Bologna (NCT07882251) Other Completed 80 Italy
11 MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Dementia & Alzheimer's · Axiom Bioregistry (NCT07892651) Other Not Yet Recruiting 5,000 Jordan
12 Remote Digital Assessments for Cognitive Disorders Dementia & Alzheimer's · Centre for Addiction and Mental Health (NCT07883746) Other Not Yet Recruiting 60 Canada
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
donepezil Death 208
memantine Death 129
rivastigmine Death 292
galantamine Fall 32
lecanemab Amyloid Related Imaging Abnormality-oedema/effusion 202

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

1,298 papers

Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Mild cognitive impairment in presymptomatic amyotrophic lateral sclerosis. McHutchison C et al. 10.1007/s00415-026-14206-0
View abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are clinically and biologically related, and each may be preceded by a prodromal stage of disease. Mild cognitive and behavioural impairment (MCI/MBI) have also been observed in those with clinically manifest ALS. The primary aim of this study was to characterise MCI in presymptomatic ALS. METHODS: Criteria for frontotemporal-related MCI (MCI-ft), which require evidence of subthreshold cognitive performance or decline, were adapted from existing frameworks for MCI in prodromal FTD, presymptomatic ALS and clinically manifest ALS. MCI-ft was characterised in 216 Pre-fALS participants (74 C9ORF72, 94 SOD1, 20 other pathogenic variant carriers and 28 non-carriers) with neuropsychological data at 807 study visits. All designations were reviewed by a research neuropsychologist, with consensus discussions as needed. RESULTS: MCI-ft was observed in 15 (20%) C9ORF72, 12 (13%) SOD1 and 3 (%) of other carriers at one or more study visits, compared to 1 (4%) non-carrier. Most visits with MCI-ft showed impairment affecting both language and executive functioning. Fluctuations in MCI-ft status between assessments were common. CONCLUSION: The observed frequency and temporal course of MCI-ft in presymptomatic ALS, using criteria based on subthreshold cognitive performance and decline, expands understanding of this phase of disease. These findings help to inform future research examining the risk of phenoconversion to clinically manifest disease and aid the design of disease prevention trials.

Journal of neurology 2026 Oct 25 PubMed
02 National memory path study: Formation of register-based cohorts of persons diagnosed with dementia in Finland in 2019 and 2021. Pulkkinen P et al. 10.1177/14034948261494819
View abstract

AIMS: This study describes the study design and methodology for the formation of novel National Memory Path cohorts, outlined to investigate dementia incidence and health and social service use preceding dementia diagnosis in Finland before and after the onset of the COVID-19 pandemic, and to enable further national-level analyses. METHODS: A register-based study was conducted, consisting of all Finnish home-dwelling adults who received a dementia diagnosis in 2019 or 2021. Dementia was defined based on the diagnosis in the Finnish Health Care Registers, or on the prescription of an anti-dementia drug in the Finnish Prescription Centre. Health and social service use within 12 months before the diagnosis included visits to outpatient and inpatient care in primary and secondary healthcare, emergency departments and home care recorded in the Finnish Health Care Registers. RESULTS: Altogether, 23,121 and 22,419 persons were diagnosed with dementia in 2019 and 2021, respectively, corresponding to an incidence of 520 and 501 per 100,000 in mean population. The highest number of diagnoses occurred in the 75-84 age group. Within 12 months before the diagnosis, 98% had used health and social services. Outpatient care in primary healthcare was the most often used service, followed by outpatient care in secondary healthcare and emergency department use. CONCLUSIONS: National health registers enable comprehensive analysis of dementia incidence and service use. Frequent service use prior to the dementia diagnosis creates opportunities for dementia symptom detection across various parts of the health and social care system.

Scandinavian journal of public health 2026 Oct 25 PubMed
03 Toward Caregiver Flourishing: A Framework for Sustainable Capacity in Dementia Care. Beckett CG 10.1177/00221465261492703
View abstract

Burden frameworks document what dementia caregiving extracts but offer limited vocabulary for how care holds together over time. This article develops flourishing, sustainable capacity under conditions, as a complementary framework. Drawing on 20 in-depth interviews with family caregivers in Emilia-Romagna, Italy, and the rural Midwest United States alongside 12 months of fieldwork, I describe four domains where caregivers performed ongoing work: connection (mobilizing actionable support), mastery (building routines and lay expertise), identity (preserving selfhood beyond care), and meaning (locating difficulty within purpose). The comparative design examines whether these domains appear across differently organized contexts; they appeared in both, although each took form according to local logics of obligation and selfhood. Caregivers sometimes reported profound strain while demonstrating expertise that had sustained care over years-a pattern suggesting burden and capability may operate as distinct dimensions. The framework offers vocabulary for describing not only what caregiving costs but also what caregivers build.

Journal of health and social behavior 2026 Oct 25 PubMed
04 Flavokawain A: a multi-targeted kava chalcone with diverse therapeutic potential. Tanwar S et al. 10.1007/s13205-026-05100-7
View abstract

G. Forst., commonly known as Kava, is a culturally significant shrub native to the Pacific islands, including Fiji, Vanuatu, and Tonga. Flavokawain A is one of the primary non-kavalactone constituents found within its rhizomes. This review aims to provide a comprehensive and critical evaluation of the current state of research on Flavokawain A. Specifically, it aims to elucidate the diverse molecular mechanisms and signaling networks that drive its pharmacological effects, while assessing its viability as a multi-targeted therapeutic candidate for diverse diseases. Flavokawain A exhibits profound therapeutic potential across a spectrum of pathological conditions, including malignancy, chronic inflammation, myocardial infarction, and neurodegenerative disorders such as Alzheimer's disease. Evidence from in silico, in vitro and in vivo models suggests that Flavokawain A's efficacy is rooted in its ability to modulate key signaling hubs, notably the TGF-β1, NF-κB, PI3K/AKT, and Nrf2 pathways, as well as regulatory proteins like PRMT5, CDK2, and SKP2. These multi-target interactions underpin Flavokawain A's potent antioxidant, anti-apoptotic, and anti-inflammatory properties, positioning it as a promising candidate for multifactorial disease management. FKA represents a versatile, multi-targeted potential therapeutic scaffold with a robust pharmacological profile. Its demonstrated anti-fibrotic, anti-inflammatory, and anti-proliferative activities across diverse disease models underscore its clinical potential. However, bridging the gap from bench to bedside requires rigorous translational studies and clinical trials to validate its safety, bioavailability, and therapeutic efficacy in human populations.

3 Biotech 2026 Nov PubMed
05 Explainable Artificial Intelligence as a Link in Dementia Patient Education: Bridging Transparency, Trust and Understanding. Sharif M et al. 10.2147/JMDH.S639856
View abstract

Dementia is a growing global health burden, and artificial intelligence (AI) is now embedded across dementia diagnosis, prognosis, and monitoring. Because many of these systems are opaque, explainable artificial intelligence (XAI) methods, such as Shapley additive explanations (SHAP), local interpretable model-agnostic explanations (LIME), and gradient-weighted class activation mapping (Grad-CAM), have been developed to make model reasoning inspectable, and they have been applied extensively to dementia diagnosis. Far less attention has been given to whether, and how, such explanations should reach the people whose lives the predictions describe. We advance this as a conceptual proposition and an underexplored opportunity, not as a finding of a systematic review. In this commentary, XAI in patient education means the third of three related but distinct things: model-level explainability, which makes a system's computation inspectable; clinician-facing interpretability, which supports professional judgment; and patient-facing explanation, which is written to be understood by the person the prediction is about. Greater model interpretability does not by itself produce greater patient understanding. We examine what would have to be true for the proposition to hold. Explanations are only as truthful as the data that feed them, so patient-facing XAI presupposes sound data governance. Explanations can mislead, increasing trust without increasing truth. Dementia is heterogeneous, so explanation must be matched to an individual's cognitive and communicative profile and retained abilities rather than to a general cognitive level. Explainability may support comprehension, but it cannot establish decision-making capacity, which is decision-specific. We therefore frame dementia education as a relational process among the person living with dementia, care partners, and clinicians, with AI in a supporting role, and outline what a deployable, governed, workflow-integrated system would require.

Journal of multidisciplinary healthcare 2026 PubMed
06 Restoration of StAR-governed neurosteroids with all-trans retinoic acid in alleviating cognitive deficits in a humanized amyloid-β knock-in mouse model of late-onset Alzheimer's disease: New insights into therapeutics. Marick A et al. 10.1016/j.neuint.2026.106280
View abstract

Alzheimer's disease (AD) is a multifactorial progressive neurodegenerative disorder of the elderly characterized by cognitive decline that involves diverse pathological processes. Aging, modulating neuronal instability, is the primary risk factor AD, resulting in dementia, for which a crucial neuropathological feature is the accumulation of amyloid-β (Aβ) plaques wherein suppression of neurosteroids plays important roles. Neurosteroidogenesis gradually decreases during aging, and the regulation of neurosteroid biosynthesis is mediated by the steroidogenic acute regulatory (StAR) protein. We demonstrate that treatment with all-trans retinoic acid (atRA, 20 mg/kg, 12-weeks) in humanized Aβ knock-in (hAbKI) mice (11-month old) resulted in increases in hippocampal StAR and sex neurosteroid (estradiol-17β/(E2) in females and testosterone in males) levels, when compared with controls. Elevated StAR and sex neurosteroid levels were associated with reductions in not only Aβ accumulation but also toxic soluble Aβ1-40 and Aβ1-42 peptides in both sexes, emphasizing an inverse correlation between neurosteroidogenesis and AD pathogenesis. Notably, atRA was capable of ameliorating cognitive impairments in both female and male hAbKI mice, as evaluated by Morris Water Maze analyses. These findings provide insights into the mechanistic events by which atRA restores neurosteroid instability, reduces neurotoxicity, and alleviates cognitive impairments in sex-specific hAbKI mice, demonstrating that retinoid therapy could serve as a novel target for the management of AD-related dementia for healthy aging.

Neurochemistry international 2026 Oct 24 PubMed
07 Cognitive Reserve Reconsidered: Asymmetry Across Proxies Challenges a Domain-General Mechanism. Paap KR et al. 10.1016/j.arr.2026.103428
View abstract

Cognitive reserve (CR) is a broad framework for explaining why individuals differ in cognitive functioning in the face of aging and neuropathology. One influential mechanistic account proposes that cognitively demanding life experiences such as education, occupational complexity, and cognitively stimulating activities augment a domain-general cognitive capacity that subsequently provides resilience. We refer to this more specific claim as cognitive reserve augmentation (CRA). This narrative and conceptual review evaluates the inferential strength of the evidence for CRA, emphasizing prospective cohort studies as the strongest available observational design for evaluating causal hypotheses. Across meta-analyses, several putative reserve-building experiences show consistent protective associations; however, comparison across prospective cohort studies reveals a striking asymmetry: whereas education, occupational complexity, and cognitively stimulating activities predict reduced risk or delayed clinical diagnosis of dementia, bilingualism-also proposed as a reserve-building cognitive experience-does not. This pattern constrains the assumption that diverse cognitive experiences augment a common reserve mechanism. Life-course evidence further indicates that associations between traditional CR proxies and later cognitive functioning can be substantially attenuated when earlier cognitive ability is measured directly. We argue that these findings are compatible with multiple pathways involving selection, correlated socioeconomic and health factors, domain-specific knowledge and expertise, processing efficiency, and effects on brain and physical health, as well as possible changes in cognitive capacity. Distinguishing among these alternatives requires specifying what experience is proposed to change, which experiences should and should not produce that change, and which outcomes would challenge the proposed mechanism. CR may therefore remain useful as a broad descriptive framework even when evidence for CRA or another specified reserve mechanism is incomplete.

Ageing research reviews 2026 Oct 24 PubMed
08 Multimodal evidence associated with 20Hz rTMS in AD: neuroaxonal injury reduction, neural oscillatory rebalancing, and multilayer network integration. Wang T et al. 10.1016/j.bbr.2026.116536
View abstract

High-frequency repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to enhance cognitive function in patients with Alzheimer's disease (AD), but the neurobiological mechanisms associated with neuroaxonal injury, neural oscillatory dynamics, and large-scale network reorganization remain unclear. In this study, we first conducted a randomized, sham-controlled trial with 16 patients with AD to evaluate the efficacy of DLPFC-targeted rTMS, followed by a single-arm multimodal cohort study of 30 patients to explore potential neurobiological mechanisms through cognitive assessments, blood biomarkers, EEG oscillatory activity, and multiplex brain network analysis. In Stage 1, the sham group showed no significant pre-post changes in MMSE or MoCA scores (MMSE: Z = -0.738, Cohen's r = 0.26; MoCA: Z =-0.853, Cohen's r = 0.30). The active rTMS group showed improvements in MMSE (Z = -2.124, Cohen's r = 0.75) and MoCA (Z = -2.108, Cohen's r = 0.75). In stage 2, rTMS was associated with improvements in MMSE (Z = -2.863, Cohen's r = 0.523) and MoCA (t = -6.137, Cohen's r = 0.752) scores. Biomarker analyses indicated a significant decrease in NfL concentrations (Z=-2.371, Cohen's r=0.484). EEG recordings revealed a decrease in delta power in the left temporal lobe (t=2.158, Cohen's r=0.372) and increases in beta power in the right parietal lobe and gamma power in the temporal lobe (beta: Z=-2.088, Cohen's r=0.381; gamma: Z=-2.129, Cohen's r=0.389). Network analysis showed reduced modularity and enhanced global efficiency across theta, alpha, and beta bands, accompanied by increased degree of overlap in frontal, parietal, and occipital regions. Importantly, MoCA improvement correlated with gamma-band global efficiency (R=0.389, P=0.034) and multilayer clustering coefficients in the left frontal and right occipital regions (R=0.478, P=0.008; R=0.398, P=0.029). Overall, rTMS exposure was associated with cognitive improvements in patients with AD, together with changes in neurodegeneration-related biomarkers and EEG network organization. These findings suggest that cognitive changes following rTMS may be associated with oscillatory modulation and large-scale network remodeling. TRIAL REGISTRATION: Registration number: ChiCTR2500095949; Registration Date: 2025-01-15.

Behavioural brain research 2026 Oct 24 PubMed
09 Decoupling neurodegenerative protein signals in biofluids via cross-reactive interfaces and inverted multi-dynamic encoders. Hwang YJ et al. 10.1016/j.bios.2026.119356
View abstract

The direct analysis of neurodegenerative proteins in complex biofluids is inherently limited by severe Debye screening and non-specific protein interference, often necessitating extensive sample dilution in conventional assays. Traditional target-specific sensors fail to extract reliable signals from these physiological matrices. Here, we present a hardware-software co-design integrating a cross-reactive tiered deoxygenation graphene oxide (TDGO) sensor with an inverted multi-dynamic encoder (IMDE) framework to simultaneously quantify multiplexed targets (Aβ, tau-441, and α-synuclein). To overcome matrix complexity, the physical interface operates under a dual-stress condition, combining inherent matrix interference with dynamic electrochemical modulation (stepped back-gate voltage, V = 0-20 V). This approach generates high-dimensional orthogonal data from non-linear sensor outputs, achieving a physical limit of detection below 0.1 pg/mL. By dynamically mapping these physical variations, the IMDE mathematically inverts the signal entanglement to achieve precise target quantification (R = 0.914) directly in protein-fortified human serum. As a proof-of-concept for clinical application, we couple the IMDE with a multi-layer perceptron downstream classifier, successfully discriminating multi-class disease states in neat transgenic mouse plasma (AUROC = 0.917). Complemented by SHAP analysis to ensure signal interpretability, this platform provides a highly transferable bioelectronic methodology for decoding non-linear physiological signals.

Biosensors & bioelectronics 2026 Oct 21 PubMed
10 Implementing the National Alzheimer's Coordinating Center Uniform Data Set (v3) within the Diabetes Prevention Program Outcomes Study. Doherty LK et al. 10.1159/ned/adwag054
View abstract

INTRODUCTION: The Diabetes Prevention Program (DPP) was a randomized clinical trial designed to prevent type 2 diabetes (T2D) in adults with prediabetes. The DPP Outcomes Study (DPPOS) is the 30-year follow-up of this cohort, focusing on T2D, prediabetes, and related complications. Cognitive assessments began in 2009 and expanded in 2022 to examine cognitive impairment, including Alzheimer's disease (AD) and AD related dementias (ADRD), in the surviving cohort. To support these aims, the National Alzheimer's Coordinating Center Uniform Data Set version 3 (NACC-UDSv3), the standardized framework used by Alzheimer's Disease Research Centers, was implemented in DPPOS in 2022 to enable data sharing with NACC. These forms were complemented by cognitive tests administered in DPPOS. We aimed to integrate the NACC-UDSv3 into the existing longitudinal DPPOS framework while maintaining fidelity to its structure and developing automated reports to streamline cognitive outcomes adjudication. METHODS: Items from the 16 NACC-UDSv3 data forms were compared with those already collected within DPPOS to integrate overlapping similar items, add missing NACC-UDSv3 items, and create a dataset harmonized with NACC-UDSv3. Forms were adapted for electronic data capture (EDC) using the MIDAS (Multimodal Integrated Data Acquisition System, George Washington University). Automated reports integrated current and prior neuropsychological scores to support adjudications. In the first wave of the DPPOS-AD/ADRD study, 1561 cognitive adjudications were successfully completed using the harmonized DPPOS and NACC-UDSv3 data implemented into MIDAS. DISCUSSION: The DPPOS-AD/ADRD project demonstrated that NACC-UDSv3 can be successfully integrated into a long-standing longitudinal cohort not originally designed for AD/ADRD research. The harmonization, electronic capture, and automated adjudication processes may provide a practical framework for other cohorts seeking to incorporate NACC-UDSv3 to align with national AD/ADRD research standards.

Neuroepidemiology 2026 Oct 24 PubMed
11 Comprehension of ambiguous sentences in Alzheimer's disease: A study with Brazilian older adults. Campanha AC et al. 10.1159/dem/aciag017
View abstract

INTRODUCTION: Language impairment is an early marker in Alzheimer's disease (AD), manifesting in both semantic memory and syntactic comprehension. The comprehension of lexical (LAS) and syntactic (SAS) ambiguous sentences requires the integrity of both systems and is particularly challenging for patients with probable AD. The study aimed to investigate differences in performance on ambiguous sentence comprehension between healthy older adults and patients with probable AD, and to identify which type of ambiguity posed the greatest difficulty for each group. METHODS: A cross-sectional observational study with 118 participants (60 patients with probable AD and 58 healthy controls) underwent an experimental task of comprehending 12 ambiguous sentences (6 LAS and 6 SAS). Multiple linear regression models were adjusted for age, sex, and education. RESULTS: Patients with probable AD performed significantly worse in LAS (β = -4.664; 95% CI: -5.827 to -3.502; p < 0.001), SAS (β = -3.259; 95% CI: -4.294 to -2.225; p < 0.001), and TAS (β = -7.776; 95% CI: -9.624 to -5.927; p < 0.001). Both groups interpreted LAS significantly better than SAS. Education was associated with better performance in all three models (p < 0.05). Age and sex were not significantly associated. CONCLUSION: Patients with probable AD present significantly impaired comprehension of ambiguous sentences, with syntactic ambiguity posing the greatest challenge. Education proved to be a protective factor. These findings reinforce the multifactorial nature of linguistic deficits in probable AD and suggest that the ambiguous sentences task is a useful tool for assessing linguistic impairment.

Dementia and geriatric cognitive disorders 2026 Oct 24 PubMed
12 Amelioration of early pathological changes in the 3xTg-AD mouse model: Mechanism of action of the Chinese herbal formula Tianqi Granules. Zhang T et al. 10.4103/NRR.NRRONLINE-D-26-00875
View abstract

Alzheimer's disease is a multifactorial neurodegenerative disorder characterized by progressive cognitive decline. This study investigated the effects of the Chinese herbal formula Tianqi Granules on early pathological progression in the 3xTg-AD mouse models and investigated the underlying mechanisms. After 31 days of Tianqi Granule treatment initiated at 5 months of age, Tianqi Granules-treated mice showed improved performance in the open-field test, novel object recognition test, and Morris water maze test. Amyloid deposition and glial activation were attenuated, and immunoreactivity for interleukin-1β and LC3 was reduced. Hippocampal transcriptome sequencing at multiple time points showed that, in untreated mice, early pathological progression occurred in three successive phases, with the dominant processes shifting from compensatory programs to failing homeostasis and subsequently to degenerative changes. Tianqi Granule treatment was associated with a three-phase response centered on the restoration of homeostasis and involving proteostasis, nuclear processes, lipid and carbohydrate metabolism, and redox-related pathways. Multiple biological domains were engaged rather than a single target. In males, an interferon-related program associated with Irf7 was induced early and shifted in the opposite direction under Tianqi Granule treatment during the same time window. Network pharmacology identified OPRK1 as the only candidate target shared by both sexes, making it a potential target for future investigation. These findings suggest that Tianqi Granule modulates the pathology of Alzheimer's disease through coordinated actions on multiple targets and may influence systemic metabolic homeostasis, providing experimental support for early therapeutic intervention in Alzheimer's disease.

Neural regeneration research 2026 Oct 24 PubMed
13 Gut Microbiota in Alzheimer's Disease and Healthy Aging: Mechanisms, Prevention Strategies and Healthcare Burden. Çeli̇k MN et al. 10.1007/s13668-026-00812-x
View abstract

PURPOSE OF REVIEW: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline associated with oxidative stress, neuroinflammation, tau neurofibrillary tangles, amyloid-beta plaque deposition, and metabolic dysfunction. Increasing evidence suggests that the gut microbiota plays an important role in AD pathogenesis through the microbiota-gut-brain axis. This review aims to provide a comprehensive overview of the role of the gut microbiota in AD and healthy aging, with a particular focus on microbiota-targeted preventive and therapeutic strategies and their potential to influence disease progression. RECENT FINDINGS: Recent studies have demonstrated that alterations in gut microbial composition are closely associated with AD. Patients with AD commonly exhibit a reduced abundance of short-chain fatty acid-producing bacteria and an increased prevalence of lipopolysaccharide-producing taxa, supporting a mechanistic link between microbial dysbiosis, systemic inflammation, and neurodegeneration. Emerging evidence indicates that dietary patterns, prebiotics, probiotics, synbiotics, postbiotics, and microbiota-based therapies, including fecal microbiota transplantation (FMT), may beneficially modulate gut microbial composition and influence AD-related pathophysiological processes. In addition, lifestyle factors such as sleep quality and physical activity have been increasingly recognized for their interactions with the gut-brain axis and their potential to affect cognitive health. Current evidence highlights the gut microbiota as a promising therapeutic target in AD prevention and management. Microbiota-directed interventions, together with healthy dietary and lifestyle modifications, may help attenuate neuroinflammation, improve metabolic homeostasis, and delay cognitive decline. Furthermore, given the substantial global economic burden of AD, microbiota-focused preventive strategies may contribute not only to improving clinical outcomes but also to reducing long-term healthcare and societal costs. Future longitudinal and interventional studies are needed to establish causal relationships and determine the efficacy of microbiota-based therapies in AD.

Current nutrition reports 2026 Oct 24 PubMed
14 Aerobic physical activity is associated with lower pneumonia and COVID-19 mortality in adults with cognitive impairment. Shin S et al. 10.1007/s11357-026-02596-y
View abstract

Cardiovascular disease and pneumonia are major causes of death in dementia, but cause-specific mortality has rarely been examined in clinically confirmed cognitive-impairment cohorts. In this nationwide retrospective cohort study, 116,563 individuals with clinically confirmed mild cognitive impairment or dementia in the Korean Dementia Relief Center registry (2016-2021) were linked to health screening and death registry data. Aerobic physical activity (APA) was quantified in metabolic-equivalent minutes per week (MET·min/week). Cox proportional hazards and Fine-Gray models estimated adjusted hazard ratios (HRs) and subdistribution HRs (sHRs). The Benjamini-Hochberg procedure controlled the false discovery rate (FDR) across 18 cause-specific comparisons. During 400,500 person-years of follow-up (mean, 3.4 years), 5022 participants (4.31%) died. Compared with inactivity, low, moderate, and high APA were associated with lower all-cause mortality (HR [95% CI], 0.728 [0.652-0.813], 0.704 [0.636-0.781], and 0.636 [0.590-0.687], respectively). High APA was associated with lower pneumonia mortality (sHR, 0.554; 95% CI, 0.437-0.702) and COVID-19 mortality (sHR, 0.520; 0.368-0.735). These point estimates were numerically lower than for ischemic heart disease and cerebrovascular disease (sHRs, 0.613 and 0.630). Pneumonia mortality was lower across all APA levels after FDR control (q ≤ 0.023). The E-value for the high APA-pneumonia association was 3.01. APA was associated with lower mortality even at modest activity levels, especially for pneumonia deaths. Achievable activity goals may therefore merit prospective evaluation as part of supportive care for adults with cognitive impairment. Because APA may also indicate preserved physiological reserve, these findings do not establish causality and require confirmation using repeated, objective activity measurements.

GeroScience 2026 Oct 24 PubMed
15 Unlocking therapeutic potential of Wnt signaling pathway in neurodegenerative diseases. Shah A et al. 10.1007/s11011-026-02006-4
View abstract

The Wnt Signaling pathway is a regulatory network that is highly conserved in the central nervous system and is essential for the survival of neurons, synaptic plasticity, and the blood-brain barrier's integrity. The pathophysiology of major neurodegenerative and neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and traumatic brain injury (TBI), is highly influenced by canonical and non-canonical Wnt Signaling dysregulation, according to increasingly compelling evidence. In addition to emphasising common molecular events such as GSK-3β overactivation, β-catenin destabilisation, neuroinflammation, synaptic dysfunction, and BBB disruption, this study offers a comparative and mechanistic overview of Wnt pathway changes across various illnesses. This article identifies overlapping treatment targets, such as GSK-3β, DKK1, LRP5/6, and Wnt ligands, by integrating common and disease-specific Wnt-associated pathways, in contrast to traditional disease-specific reviews. Furthermore, new translational approaches involving natural substances, Wnt modulators, and pathway-targeted treatments are critically examined. All things considered, this study presents Wnt Signaling as a potential neuroprotective and regenerative target for upcoming precision-based treatments in neurodegenerative disorders.

Metabolic brain disease 2026 Oct 24 PubMed
16 Improving the clinical trial landscape for Parkinson syndromes in Germany. Höglinger G et al. 10.1007/s00702-026-03314-w
View abstract

Germany has a longstanding tradition of excellence in neuroscience and Parkinson's research, supported by outstanding academic institutions, specialized clinical centers, and a strong scientific community. Building on this strong foundation, the country now has the opportunity to transform its clinical research landscape into a more integrated ecosystem for Parkinson syndromes. Despite major advances in molecular understanding, biomarker development, and therapeutic innovation, important structural, regulatory, financial, and organizational barriers continue to limit the full translational potential of German Parkinson research. Participants in an expert workshop identified identify recurring challenges, including fragmented trial infrastructures, slow and bureaucratic regulatory procedures, insufficient funding for investigator-initiated clinical research, limited integration of patient organizations, and suboptimal patient recruitment pathways. This workshop-derived perspective outlines a strategic framework to elevate Germany from a country with excellent individual centers to a globally competitive and integrated hub for innovative Parkinson clinical research. Key recommendations include transforming the German Parkinson Study Group into a nationally coordinated, service-oriented trial network; establishing centralized digital and regulatory infrastructures; diversifying public and philanthropic funding; implementing platform and observational trial structures; strengthening incentives for participating centers; and enhancing patient engagement through national registries, decentralized trial approaches, real-world data based evidence surveillance, and systematic integration of patient organizations. The authors argue that Germany must move beyond isolated university-based structures toward a nationally coordinated and highly efficient research ecosystem capable of rapidly delivering disease-modifying and precision medicine trials. Such a transformation could strengthen Germany's international position in neurodegenerative disease research and accelerate therapeutic innovation for patients with Parkinson syndromes.

Journal of neural transmission (Vienna, Austria : 1996) 2026 Oct 24 PubMed
17 Geissoschizine methyl ether can be simultaneously measured with rhynchophylline and hirsutine in Yokukansan extract. Tsuge A et al. 10.1007/s11418-026-02094-7
View abstract

Yokukansan (YKS) is a Kampo prescription used to treat neurosis, insomnia, and behavioral and psychological symptoms of dementia (BPSD). Previous studies have reported that geissoschizine methyl ether (GM), an indole alkaloid from Uncaria species, is the principal active constituent of YKS in the treatment of BPSD. Within YKS, GM originates from Uncaria Hook (UH), a component of natural drugs. Rhynchophylline (RIN) and hirsutine (HIR) are specified as quantitative marker constituents of YKS in the Japanese Pharmacopoeia 18th Revision (JP18) to determine the total alkaloid content. Given the recent focus on the pharmacological activity of GM, this study examined an HPLC method for detecting GM, RIN, and HIR in YKS extracts. RIN, HIR, and GM were detected as well-resolved peaks in the YKS extract under JP18 assay conditions. Comparison with the Uncaria Hook-depleted YKS extract showed no apparent matrix interference at the retention times of these alkaloids. In addition, this method was applied to most of the tested C18 columns, meeting the JP18 specifications. These findings indicate that the Japanese Pharmacopoeia assay framework can be extended to enable concurrent measurement of GM, RIN, and HIR in YKS extracts, thereby providing additional alkaloid information without requiring a separate GM-specific assay.

Journal of natural medicines 2026 Oct 24 PubMed
18 The Multi-Faceted Nature of Limb Apraxia in Neurodegenerative Diseases: a Systematic Review. Guézouli L et al. 10.1007/s11065-026-09697-7
View abstract

This systematic review aims to expand the characterization of apraxia in a spectrum of different neurodegenerative diseases and to explore associations between apraxia, on the one hand, and motor and cognitive disorders, on the other hand. 32 studies were included, representing a total of 430 patients with neurodegenerative diseases (n = 146 cases with CBS; n = 104 cases with SD; n = 66 cases with PD; n = 92 cases with bvFTD; n = 22 cases with PCA). The findings highlight that limb apraxia is multi-faceted in neurodegenerative diseases, as patients show polymorphic praxic performances depending on the cognitive disorders and the patterns of cortical or subcortical atrophy they exhibit. (1) According to a cortico-subcortical axis, patients with CBS are more impaired in gesture production than patients with PD. Whether gesture impairments met in PD are due to motor deficits or "true" apraxia remains an open issue. (2) According to a dorso-ventral axis, there is a double dissociation between gesture production that is better preserved in SD than in CBS, and semantic knowledge that is better preserved in CBS than in SD. (3) According to an antero-posterior axis, more data are needed to explore apraxia and its links with social and visual spatial skills in the behavioral variant of frontotemporal dementia and in posterior cortical atrophy. Overall, our review emphasizes the need to adopt a process-based approach to better understand the nature of gesture impairments in each syndrome.

Neuropsychology review 2026 Oct 24 PubMed
19 Comparative Hippocampal and Serum Metabolomics Reveals Dose-related Metabolic Alterations Consistent with TDMQ20 Intervention in a Cu-Aβ₄₂-induced Mouse Model. Ayesha Q et al. 10.1007/s12035-026-06286-w
View abstract

Copper (Cu) dyshomeostasis and metabolic dysfunction have been implicated as key drivers of Alzheimer's disease (AD). Tetradentate monoquinoline 20 (TDMQ20), a Cu chelator, reportedly improves behavioral deficits in AD model mice, but its underlying metabolic mechanism is unclear. Here, we addressed this via untargeted ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) metabolomics in the hippocampus and serum of AD model mice induced by intrahippocampal injection of Cu amyloid-β (Cu-Aβ₄₂) and then treated with TDMQ20 at low (LT, 5 mg/kg) and high (HT, 10 mg/kg) doses. Results showed that AD was associated with tissue-specific metabolic perturbations: hippocampal disorders were enriched in linoleic acid and glycerophospholipid metabolism, while serum perturbations centered on tryptophan, sphingolipid, and purine metabolism, with organic acids, lipids, and benzenoids as core differential metabolite classes. TDMQ20 reversed these abnormalities in a dose-associated manner: LT regulated tryptophan/linoleic acid metabolism in the hippocampus and purine/arachidonic acid metabolism in serum, while HT shifted the hippocampal metabolic profile substantially toward that of the control group. Cross-matrix analysis identified PS (15:0/22:0) and LPC (18:2/0:0) as key lipid metabolites with opposite expression patterns between hippocampus and serum, and four serum endogenous metabolites (pipecolic acid, PGG2, N-sulfo-D-glucosamine, and hex-2-ulose) as exploratory candidate metabolites. TDMQ20 was associated with metabolomic changes in both hippocampus and serum consistent with attenuated oxidative stress, neuroinflammation, and membrane lipid remodeling, suggesting preferential central metabolic modulation and dose-associated action. This study provides metabolomic evidence consistent with TDMQ20's potential tissue-resolved regulatory properties and identifies exploratory candidate metabolites for monitoring therapeutic efficacy in AD.

Molecular neurobiology 2026 Oct 24 PubMed
20 Sex differences in the association of late-life blood pressure decline with postmortem brain vessel pathology. Baumgartner NW et al. 10.1007/s00401-026-03107-1
View abstract

Although hypertension is the leading modifiable risk factor for cerebrovascular disease, less is known about the relation of late-life change in blood pressure (BP) and cerebrovascular pathology beyond brain infarcts. Our previous work found sex-specific associations between declining systolic BP (SBP) and cognitive decline in late-life, suggesting that cerebrovascular pathology may be an upstream contributor to these sex differences. However, postmortem studies have not examined whether BP change differentially relates to vascular brain pathology in men and women, despite well-established sex differences in BP trajectories and cerebrovascular pathology. We examined associations between change in late-life BP and postmortem cerebrovascular (arteriolosclerosis, atherosclerosis, and cerebral amyloid angiopathy) pathology from 2033 community-dwelling older adults (mean baseline age = 79.7 [SD = 7.1] years; 69% women) from four longitudinal cohort studies with brain autopsy (mean age-at-death = 89.8 [6.6] years). Person-specific late-life BP slopes estimated from annual clinical evaluations over an average of 9.1 [5.7] years were entered in ordinal regressions adjusted for age-at-death, sex, antihypertensive medication use, and BP slope × sex, age-at-death × sex, and BP slope × age-at-death interactions. Faster SBP decline was associated with greater severity of arteriolosclerosis (OR = 1.24, 95%CI 1.08-1.42) and atherosclerosis (OR = 1.41, 95%CI 1.22-1.63). A sex × SBP slope interaction (p = 0.01) revealed a stronger association of SBP decline with arteriolosclerosis severity in women than men. This longitudinal, clinical-pathologic study of older decedents showed sex differences in the association of declining SBP in late-life with severity of arteriolosclerosis, extending prior associations with cognitive decline to cerebrovascular pathology, and suggests potential for longitudinal BP monitoring for precision medicine approaches in cerebrovascular disease risk stratification.

Acta neuropathologica 2026 Oct 24 PubMed
21 Neurotrophic regulation of lipid metabolism in Alzheimer's disease: Mechanisms and therapeutic implications. Fan D et al. 10.1177/13872877261499707
View abstract

BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder in which lipid metabolic dysregulation is increasingly recognized as an important contributor to pathogenesis. Neurotrophic factors (NTFs), beyond their established roles in neuronal survival and synaptic plasticity, may also regulate lipid metabolism.ObjectiveTo summarize current evidence on lipid metabolic dysregulation in AD and evaluate the potential roles of major NTFs in regulating lipid homeostasis.MethodsExperimental, clinical, and translational studies addressing lipid metabolism, neurotrophic signaling, and their interactions in AD were reviewed, focusing on cholesterol, sphingolipid, and fatty acid metabolism and on BDNF, NGF, GDNF, CNTF, and Nrn1.ResultsDisturbances in cholesterol transport, sphingolipid and fatty acid metabolism, and high-density lipoprotein function may promote AD pathology by affecting membrane organization, synaptic plasticity, oxidative stress, insulin signaling, and amyloid-β and tau metabolism. BDNF, NGF, GDNF, CNTF, and Nrn1 may influence lipid-related processes through pathways including PI3K/Akt, AMPK, MAPK, and STAT3. However, evidence strength varies substantially among NTFs, and many proposed interactions are supported mainly by cellular, animal, or non-AD models.ConclusionsNeurotrophic signaling and lipid metabolism may form an interconnected regulatory network relevant to AD pathophysiology. This concept may support future biomarker and therapeutic research, but it should currently be regarded as a hypothesis-generating framework requiring direct validation in human AD and well-characterized AD models.

Journal of Alzheimer's disease : JAD 2026 Oct 24 PubMed
22 Sex differences in exercise-induced pro-inflammatory cytokine responses relevant to Alzheimer's disease: A systematic review and meta-analysis. Lee H et al. 10.1177/13872877261500635
View abstract

BackgroundChronic inflammation contributes to the pathogenesis of Alzheimer's disease (AD), and physical exercise is a promising nonpharmacological strategy for modulating systemic inflammatory responses. However, evidence regarding sex- and exercise type-specific effects on AD-related pro-inflammatory cytokines remains fragmented.ObjectiveTo quantitatively synthesize evidence on sex differences in inflammatory cytokine responses relevant to AD according to exercise type, focusing on tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β).MethodsA systematic search identified randomized controlled trials (RCTs) examining the effects of aerobic exercise (AE), resistance exercise (RE), and combined exercise (CE) on circulating cytokines in adult men and women. Percentage changes from pre- to post-intervention were extracted and pooled using random-effects meta-analyses. Subgroup analyses were conducted by sex, exercise type, cytokine, and menopausal status.ResultsThirty-two RCTs involving approximately 1200 participants were included. TNF-α showed the most consistent response, with significant reductions after AE and CE in both sexes, whereas RE reduced TNF-α primarily in women. IL-6 decreased across exercise type-dependent modalities, with the largest reductions following AE and no consistent sex-specific differences. Effects on IL-1β were limited and largely nonsignificant across exercise types.ConclusionsExercise-induced modulation of inflammatory cytokines relevant to AD is cytokine-specific and exercise type-dependent, with additional influence from biological sex. TNF-α appears most responsive to exercise, supporting AE and CE as potential strategies to mitigate systemic inflammation associated with AD risk. Further trials are needed to clarify sex-specific mechanisms and the clinical relevance of exercise-induced inflammatory modulation across the AD continuum.

Journal of Alzheimer's disease : JAD 2026 Oct 24 PubMed
23 Diabetes mellitus accelerates preclinical Alzheimer's disease progression by amplifying the amyloid-to-tau pathway and attenuating brain-cognition resilience. Jin H et al. 10.1177/13872877261500770
View abstract

BackgroundDiabetes mellitus (DM) is a risk factor for Alzheimer's disease (AD), but its stage-dependent effects on the ATN framework remain unclear.ObjectiveTo determine whether DM differentially affects clinical progression from cognitively normal (CN) to mild cognitive impairment (MCI) versus MCI to AD, how DM modulates the ATN cascade, and the optimal follow-up for detecting structural-cognitive changes.MethodsWe analyzed longitudinal data from 1638 ADNI participants (765 CN, 71 with DM; 873 MCI, 91 with DM). Clinical progression was assessed by Cox regression. Annualized slopes of ATN biomarkers and cognition were estimated. Moderation analyses tested DM × predictor interactions on A→T (amyloid→tau) and N→C (neurodegeneration→cognition) pathways with FDR correction. Piecewise linear mixed models identified the optimal knot for structural-cognitive coupling.ResultsDM increased CN-to-MCI risk (adjusted HR = 1.73, p = 0.028) but not MCI-to-AD progression (adjusted HR = 1.10, p = 0.574). In CN, DM amplified amyloid-driven tau accumulation in entorhinal cortex (A→T interaction β = 0.77, FDR p = 0.043) and attenuated the protective effect of hippocampal volume on cognition (e.g., hippocampal volume slope × DM on MMSE slope: β = -0.19, FDR p = 0.031). These effects were absent in MCI (all FDR p > 0.05). A 36-month follow-up was the optimal window for detecting robust structural-cognitive coupling in the CN cohort, independent of DM status.ConclusionsDiabetes accelerates preclinical AD by amplifying A→T and eroding structural-cognitive resilience, but does not hasten progression from established MCI to AD. A minimum 36-month observation period is recommended for early-phase prevention trials.

Journal of Alzheimer's disease : JAD 2026 Oct 24 PubMed
24 Neuroprotective potential of woohwangchungsimwon for dementia and mild cognitive impairment: Its key components, compounds, and bioactivities. Jeong Y et al. 10.1177/13872877261499735
View abstract

Dementia is a progressive neurodegenerative disorder characterized by cognitive decline that compromises daily functioning, with Alzheimer's disease (AD) representing its most prevalent form. Mild cognitive impairment (MCI) represents a prodromal stage of AD and provides an important window for early intervention. Woohwangchungsimwon (WCW) is a multicomponent natural medicinal formulation historically used to promote cardiovascular and neurological stability and to alleviate excessive heat and phlegm. This review evaluated the potential of WCW to ameliorate symptoms associated with dementia and MCI. A narrative review of experimental and pharmacological studies was conducted to examine the bioactive compounds, bioactivities, mechanisms, and reported outcomes of eight key natural medicinal components of WCW: Angelicae Gigantis Radix, Calculus Bovis, Cinnamomi Cortex, Dioscoreae Rhizoma, Ginseng Radix, Glycyrrhizae Radix, Hoelen and Zingiberis Rhizoma, which possess neuroprotective, anti-inflammatory and antioxidant activities. Although current evidence regarding WCW and its active components is derived predominantly from preclinical models and studies conducted within broader neurological contexts, its multicomponent nature suggests significant potential for targeting multiple pathological processes relevant to dementia and MCI. Well-designed clinical trials are now needed to clarify the therapeutic efficacy and safety of WCW in patients with cognitive impairment.

Journal of Alzheimer's disease : JAD 2026 Oct 24 PubMed
25 Physical activity and brain aging in Sub-Saharan Africa: A scoping review of observational studies. Yenesew MA et al. 10.1177/13872877261499670
View abstract

Physical activity may delay cognitive decline, but evidence from Sub-Saharan Africa (SSA) remains limited. This review summarizes findings on associations between physical (in)activity and brain aging in SSA, identifies research gaps and limitations, and proposes steps to strengthen research capacity. We searched five databases including PubMed using pertinent keywords. Observational studies conducted in SSA that examined physical (in)activity or related variables such as exercise as predictors and brain aging outcomes such as cognitive impairment or dementia were included. The review followed the PRISMA-ScR guidelines. Of 10,880 identified records, 19 studies met the inclusion criteria (18 cross-sectional, 1 longitudinal). Sample sizes ranged from 70 to 5,011 participants. Studies varied in design and assessment of exposures and outcomes. Seven studies reported associations between physical inactivity or lower physical activity levels and less favourable brain aging outcomes, including increased risk of cognitive impairment. Three studies found associations between higher physical activity or physical function and more favourable brain aging outcomes. Nine studies reported no associations between physical (in)activity and brain aging. Overall, the limited number of available studies, most of which were cross-sectional, leaves major gaps in understanding the role of physical (in)activity in brain aging across SSA. The evidence base is methodologically heterogeneous, with inconsistent assessment methods, limited consideration of contextual factors, and lack of longitudinal data, precluding conclusions regarding causality. This highlights the need for longitudinal research within a coordinated research ecosystem in SSA to generate robust evidence that can inform policy and support healthy brain aging across the region.

Journal of Alzheimer's disease : JAD 2026 Oct 24 PubMed
26 Undiagnosed dementia in underserved African American populations: Missed opportunities for care. G. Cohen et al. 10.1016/j.inpsyc.2026.100208 International psychogeriatrics 2026 Scholar
27 Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation. Chuo-Yu Lee et al. 10.1186/s13195-026-02095-4 Alzheimer's research & therapy 2026 Scholar
28 Biopsychosocial risk factors for Alzheimer’s disease and related dementias in UK immigrants from the Middle East and North Africa (MENA) Elizabeth Haddad et al. 10.64898/2026.05.08.26352762 medRxiv 2026 Scholar
29 Decreased Length of Locus Coeruleus Norepinephrine Axons and Increased Amyloid Beta Pathology in Male APP/PS1 Mice During Protracted Abstinence From Alcohol Ivy J. Z. Garland et al. 10.1007/s12640-026-00794-2 Neurotoxicity Research 2026 Scholar
30 Causes of death in patients with dementia: A study in a geriatric hospital in São Paulo, Brazil Yngrid Dieguez Ferreira et al. 10.1177/13872877261445578 Journal of Alzheimer's Disease 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Dementia & Alzheimer's
  • Week: October 19 – October 26, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 11:28 PM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —